Compare BioNano Genomics Inc (BNGO) vs DoorDash Inc (DASH) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
BioNano Genomics Inc vs DoorDash Inc — how do they compare? BioNano Genomics Inc trades at $1.19 (market cap $13.66M), while DoorDash Inc trades at $214.14 (market cap $91.86B). The key difference: DoorDash Inc is far larger — about 6724.7× BioNano Genomics Inc's market cap, and DoorDash Inc is trading nearer its 52-week high, BioNano Genomics Inc nearer its low. Which is the better fit depends on your goals.
| BNGO | DASH | |
|---|---|---|
Market Cap | $13.66M | $91.86B |
Sector | Health | Consumer Cyclical |
52-Week High | $4.92 | $281.74 |
52-Week Low | $1.06 | $146.60 |
Enterprise Value | $16.26M | $89.82B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
BNGO trades at $1.16 with a bullish technical signal supported by moving averages. The company shows improving financial trends with narrowing losses and consistent earnings beats, though it remains unprofitable with negative margins. Recent news highlights operational progress including debt retirement and scientific publications. Valuation ratios appear attractive with P/S of 0.31 and P/B of 0.36.
The outlook remains speculative given persistent losses, but improving cash flow trends and analyst optimism provide catalysts. Key risks include ongoing negative profitability and competitive pressures in genomics. With 57% analyst buy ratings and bullish technical momentum, the stock offers high-risk growth potential for investors comfortable with biotech volatility.
DoorDash (DASH) trades at $209.86, down 2.96% today, amid mixed earnings results but strong revenue growth. The stock shows a bullish technical trend above key support levels, with a 75.68% analyst buy rating. Recent Q2 2026 revenue beat expectations, though EPS missed due to higher R&D costs, while the company projects robust Q3 growth and continues investing in AI and autonomous delivery.
Outlook remains positive driven by expanding market share and profitability, but risks include intense competition and cost pressures. The consensus price target of $247.41 suggests ~18% upside, supported by solid cash flow and strategic acquisitions, though valuation multiples are elevated.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About BioNano Genomics Inc
Bionano Genomics Inc is a life sciences instrumentation company in the genome analysis space. It is engaged in the development and marketing of the Saphyr system, a platform for ultra-sensitive and ultra-specific structural variation detection that enables researchers and clinicians to accelerate the search for new diagnostics and therapeutic targets and to streamline the study of changes in chromosomes.
Read more on BNGO →About DoorDash Inc
Founded in 2013 and headquartered in San Francisco, DoorDash is an online food order demand aggregator. Consumers can use its app to order food on-demand for pickup or delivery from merchants mainly in the U.S. The firm provides a marketplace for the merchants to create a presence online, market their offerings, and meet demand by making the offerings available for pickup or delivery. The firm provides similar service to businesses in addition to restaurants, such as grocery, retail, pet supplies, and flowers. At the end of 2020, DoorDash had over 450,000 merchants, 20 million consumers, and over 1 million dashers on its platform. In 2020, the firm generated $24.7 billion in gross order volume (up 207% year over year) and $2.9 billion in revenue (up 226%).
Read more on DASH →
